Marc Goodman
Stock Analyst at Leerink Partners
(3.69)
# 747
Out of 5,135 analysts
93
Total ratings
58.44%
Success rate
29.88%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $184.74 | +10.97% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $3.59 | +122.84% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $17.31 | +73.31% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $1.46 | +242.47% | 1 | Nov 17, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $24.07 | +41.25% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $11.54 | +333.28% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $14.10 | -29.08% | 5 | May 7, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $4.08 | -75.49% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $12.77 | +150.59% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $173.93 | -85.63% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $19.23 | +160.01% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $4.34 | +360.83% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $128.38 | -10.42% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $194.13 | +59.69% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $42.47 | +8.31% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $23.19 | -9.44% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $168.72 | +24.47% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.61 | +283.85% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $32.02 | -15.68% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.02 | +198.80% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $689.42 | -60.84% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $228.72 | -58.03% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $59.73 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $121.66 | -44.93% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $14.58 | +572.15% | 7 | Oct 5, 2017 |
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $184.74
Upside: +10.97%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $3.59
Upside: +122.84%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $17.31
Upside: +73.31%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $1.46
Upside: +242.47%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $24.07
Upside: +41.25%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $11.54
Upside: +333.28%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $14.10
Upside: -29.08%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $4.08
Upside: -75.49%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $12.77
Upside: +150.59%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $173.93
Upside: -85.63%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $19.23
Upside: +160.01%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $4.34
Upside: +360.83%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $128.38
Upside: -10.42%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $194.13
Upside: +59.69%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $42.47
Upside: +8.31%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $23.19
Upside: -9.44%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $168.72
Upside: +24.47%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.61
Upside: +283.85%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $32.02
Upside: -15.68%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.02
Upside: +198.80%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $689.42
Upside: -60.84%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $228.72
Upside: -58.03%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $59.73
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $121.66
Upside: -44.93%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $14.58
Upside: +572.15%